Clinical Trials
3 trialsNCT03065062 2026-02-13
Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors
Dana-Farber Cancer Institute
Phase 1 Suspended
NCT03675893 2025-06-15
RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT02069158 2019-05-21
IOSI-NDU-001
Oncology Institute of Southern Switzerland
Phase 1 Completed